FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285806444> ?p ?o ?g. }

• W4285806444 endingPage "e004464" @default.
• W4285806444 startingPage "e004464" @default.
• W4285806444 abstract "Many solid tumors do not respond to immunotherapy due to their immunologically cold tumor microenvironment (TME). We and others found that oncolytic viruses (OVs), including reovirus type 3 Dearing, can enhance the efficacy of immunotherapy by recruiting CD8+ T cells to the TME. A significant part of the incoming CD8+ T cells is directed toward reovirus itself, which may be detrimental to the efficacy of OVs. However, here we aim to exploit these incoming virus-specific T cells as anticancer effector cells.We performed an in-depth characterization of the reovirus-induced T-cell response in immune-competent mice bearing pancreatic KPC3 tumors. The immunodominant CD8+ T-cell epitope of reovirus was identified using epitope prediction algorithms and peptide arrays, and the quantity and quality of reovirus-specific T cells after reovirus administration were assessed using high-dimensional flow cytometry. A synthetic long peptide (SLP)-based vaccination strategy was designed to enhance the intratumoral frequency of reovirus-specific CD8+ T cells.Reovirus administration did not induce tumor-specific T cells but rather induced high frequencies of reovirus-specific CD8+ T cells directed to the immunodominant epitope. Priming of reovirus-specific T cells required a low-frequent population of cross-presenting dendritic cells which was absent in Batf3-/- mice. While intratumoral and intravenous reovirus administration induced equal systemic frequencies of reovirus-specific T cells, reovirus-specific T cells were highly enriched in the TME exclusively after intratumoral administration. Here, they displayed characteristics of potent effector cells with high expression of KLRG1, suggesting they may be responsive against local reovirus-infected cells. To exploit these reovirus-specific T cells as anticancer effector cells, we designed an SLP-based vaccination strategy to induce a strong T-cell response before virotherapy. These high frequencies of circulating reovirus-specific T cells were reactivated on intratumoral reovirus administration and significantly delayed tumor growth.These findings provide proof of concept that OV-specific T cells, despite not being tumor-specific, can be exploited as potent effector cells for anticancer treatment when primed before virotherapy. This is an attractive strategy for low-immunogenic tumors lacking tumor-specific T cells." @default.
• W4285806444 created "2022-07-19" @default.
• W4285806444 creator A5005383720 @default.
• W4285806444 creator A5013338958 @default.
• W4285806444 creator A5016385609 @default.
• W4285806444 creator A5041281028 @default.
• W4285806444 creator A5050077644 @default.
• W4285806444 creator A5050234368 @default.
• W4285806444 creator A5066928235 @default.
• W4285806444 creator A5068769338 @default.
• W4285806444 creator A5070212585 @default.
• W4285806444 creator A5072951992 @default.
• W4285806444 creator A5084725629 @default.
• W4285806444 creator A5088317623 @default.
• W4285806444 date "2022-07-01" @default.
• W4285806444 modified "2023-09-30" @default.
• W4285806444 title "Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy" @default.
• W4285806444 cites W1547235334 @default.
• W4285806444 cites W1596643341 @default.
• W4285806444 cites W1827720726 @default.
• W4285806444 cites W1949342640 @default.
• W4285806444 cites W1965295123 @default.
• W4285806444 cites W1980784287 @default.
• W4285806444 cites W1984170705 @default.
• W4285806444 cites W1992995822 @default.
• W4285806444 cites W2008620560 @default.
• W4285806444 cites W2010213883 @default.
• W4285806444 cites W2013177587 @default.
• W4285806444 cites W2015720380 @default.
• W4285806444 cites W2028658614 @default.
• W4285806444 cites W2030523225 @default.
• W4285806444 cites W2046505430 @default.
• W4285806444 cites W2050987476 @default.
• W4285806444 cites W2070570719 @default.
• W4285806444 cites W2099092516 @default.
• W4285806444 cites W2112643590 @default.
• W4285806444 cites W2126015139 @default.
• W4285806444 cites W2128892990 @default.
• W4285806444 cites W2150912703 @default.
• W4285806444 cites W2337430744 @default.
• W4285806444 cites W2507608410 @default.
• W4285806444 cites W2615468880 @default.
• W4285806444 cites W2742865981 @default.
• W4285806444 cites W2754660884 @default.
• W4285806444 cites W2781905683 @default.
• W4285806444 cites W2781931068 @default.
• W4285806444 cites W2785396374 @default.
• W4285806444 cites W2787997309 @default.
• W4285806444 cites W2803616070 @default.
• W4285806444 cites W2804073610 @default.
• W4285806444 cites W2807014879 @default.
• W4285806444 cites W2807944903 @default.
• W4285806444 cites W2914458679 @default.
• W4285806444 cites W2918982083 @default.
• W4285806444 cites W2944507671 @default.
• W4285806444 cites W2946458937 @default.
• W4285806444 cites W2973738313 @default.
• W4285806444 cites W2988731068 @default.
• W4285806444 cites W2990200213 @default.
• W4285806444 cites W3005532091 @default.
• W4285806444 cites W3006687635 @default.
• W4285806444 cites W3012532724 @default.
• W4285806444 cites W3013943237 @default.
• W4285806444 cites W3043578946 @default.
• W4285806444 cites W3092306917 @default.
• W4285806444 cites W3093545339 @default.
• W4285806444 cites W3097960135 @default.
• W4285806444 cites W3103755024 @default.
• W4285806444 cites W3170548866 @default.
• W4285806444 cites W3210379571 @default.
• W4285806444 doi "https://doi.org/10.1136/jitc-2021-004464" @default.
• W4285806444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35853671" @default.
• W4285806444 hasPublicationYear "2022" @default.
• W4285806444 type Work @default.
• W4285806444 citedByCount "4" @default.
• W4285806444 countsByYear W42858064442022 @default.
• W4285806444 countsByYear W42858064442023 @default.
• W4285806444 crossrefType "journal-article" @default.
• W4285806444 hasAuthorship W4285806444A5005383720 @default.
• W4285806444 hasAuthorship W4285806444A5013338958 @default.
• W4285806444 hasAuthorship W4285806444A5016385609 @default.
• W4285806444 hasAuthorship W4285806444A5041281028 @default.
• W4285806444 hasAuthorship W4285806444A5050077644 @default.
• W4285806444 hasAuthorship W4285806444A5050234368 @default.
• W4285806444 hasAuthorship W4285806444A5066928235 @default.
• W4285806444 hasAuthorship W4285806444A5068769338 @default.
• W4285806444 hasAuthorship W4285806444A5070212585 @default.
• W4285806444 hasAuthorship W4285806444A5072951992 @default.
• W4285806444 hasAuthorship W4285806444A5084725629 @default.
• W4285806444 hasAuthorship W4285806444A5088317623 @default.
• W4285806444 hasBestOaLocation W42858064441 @default.
• W4285806444 hasConcept C147483822 @default.
• W4285806444 hasConcept C154317977 @default.
• W4285806444 hasConcept C159047783 @default.
• W4285806444 hasConcept C167672396 @default.
• W4285806444 hasConcept C195616568 @default.
• W4285806444 hasConcept C202751555 @default.
• W4285806444 hasConcept C203014093 @default.

• next